CTRI/2019/03/018300尚未招募4 期
Safety and efficacy study of Azadine® (Azacitidine) in treatment of myelodysplatic syndrome in Indian patients
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients of greater than or equal to 18 years of age at the time of signing the informed consent document
- •2. Histologically or cytologically documented diagnosis of MDS.
- •3. Performance status of 0, 1 or 2 by the ECOG scale, and estimated life expectancy of at least 6 months
- •4. Adequate organ function
- •5. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
- •6. Able to adhere to the study visit schedule and other protocol requirements
- •7. Must have recovered from all toxic effects of prior therapy for myelodysplastic syndrome and not received any chemotherapy for a minimum of 4 weeks prior to the first dose of study drug
排除标准
- •1. Known allergy or hypersensitivity to azacitidine or mannitol or any other component of the formulation
- •2. Sex and Reproductive Status
- •o Women of child bearing potential (WOCBP) who are unwilling or unable to use an physician-approved contraceptive method with low failure rate (less than 1 percentage per year when used consistently and correctly) to avoid pregnancy for the entire study period and for up to 3 months after the last dose of azacitidine
- •o Women who are pregnant and breastfeeding
- •o Women with a positive pregnancy test on screening or within 72 hours prior to first azacitidine administration
- •o Male subjects with a female partner of childbearing potential must agree to the
- •use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the study and for 3 months following the last dose of azacitidine
- •3. Relapsed or Refractory OR Hypoplastic OR Secondary myelodysplastic syndromes (MDS)
- •4. Prior history of acute myeloid leukemia (AML)
- •5. Patients must not have undergone prior allogeneic stem cell or bone marrow transplantation at any time
- •6. Patients must not have received lenalidomide, vorinostat or other histone
- •deacetylase (HDAC) inhibitor, or hypomethylating agents (azacitidine, decitabine) as treatment previously
- •7. Treatment with erythropoietin or myeloid growth factors (granulocyte colonystimulating
- •factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM-CSF]) during the 21 days prior to Day 1 of Cycle 1
- •8. Treatment with androgenic hormones during the 14 days prior to Day 1 of Cycle 1
- •9. Patients with active malignancy of other type than required for this study are not eligible with the exception of currently treated basal cell, squamous cell carcinoma
- •of the skin, or carcinoma in situ of the cervix or breast
- •10. Diagnosis of metastatic disease and malignant hepatic tumors
- •11. Must not have associated autoimmune hemolytic anemia or immune thrombocytopenia and inaspirable bone marrow
- •12. Known positive serology for hepatitis B surface antigen (HBsAg), hepatitis C antibody (Anti-HCV Ab) or human immunodeficiency virus (HIV)
- •13. Treatment with any other investigational drugs during prior 30 days or 5 half-lives
- •prior to first study treatment, whichever is longer
- •14. Documented serum folate deficiency or vitamin B12 deficiency within the last 28-
- •day before enrolment
- •15. Must not have a mental illness or any other condition (eg, uncontrolled cardiac or pulmonary disease, diabetes), that could prevent full cooperation with the study
- •requirements
- •16. Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study OR would prevent that person from giving informed consent OR confounds the ability to interpret data from the study
研究者
相似试验
进行中（未招募）
不适用
Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSFow and intermediate-1 risk MDS, and low-risk CMML.MedDRA version: 12.0Level: LLTClassification code 10009018Term: Chronic myelomonocytic leukaemiaMedDRA version: 12.0Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011483-11-DKMDSG30
进行中（未招募）
不适用
Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSFow and intermediate-1 risk MDS, and low-risk CMML.MedDRA version: 12.0Level: LLTClassification code 10009018Term: Chronic myelomonocytic leukaemiaMedDRA version: 12.0Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011483-11-SEMDSG30
进行中（未招募）
不适用
A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed treatment with corticosteroidsChronic Graft versus Host DiseaseMedDRA version: 18.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-005659-19-GBniversity of Birmingham
进行中（未招募）
不适用
?Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk myelodysplastic syndromes (MDSs)? - MDS0706EUCTR2007-003943-55-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
已完成
不适用
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia PatientsLeukemia, Myeloid, AcuteNCT05471700Zhujiang Hospital40